IN8bio, Inc.
INAB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $2 | $3 | $4 |
| G&A Expenses | $2 | $3 | $3 | $3 |
| SG&A Expenses | $2 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $4 | $5 | $6 | $6 |
| Operating Income | -$4 | -$5 | -$6 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -1.24 | -0.067 | -0.085 |
| % Growth | 31.5% | -1,764.7% | 21.8% | – |
| EPS Diluted | -0.85 | -1.24 | -0.067 | -0.085 |
| Weighted Avg Shares Out | 5 | 4 | 83 | 57 |
| Weighted Avg Shares Out Dil | 5 | 4 | 83 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$3 | -$4 | -$5 | -$6 |
| % Margin | – | – | – | – |